Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GRN | P28799 | 1/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144935 | 0.89 | GRN (0.36) | TDP1ALDH1A1GRNSORT1 | |
| SCHEMBL9290922 | 0.82 | TET2 (0.39) | TDP1ALDH1A1GRNSORT1 | |
| SCHEMBL4144659 | 0.81 | ALDH1A1 (0.36) | ALDH1A1TSHR | |
| SCHEMBL4151249 | 0.79 | ALDH1A1 (0.41) | TDP1ALDH1A1HSD17B10TSHR | |
| SCHEMBL31338797 | 0.79 | ALDH1A1 (0.41) | TDP1ALDH1A1HSD17B10TSHR | |
| SCHEMBL19428158 | 0.76 | TSHR (0.31) | TSHR | |
| SCHEMBL28389057 | 0.75 | HSD17B10 (0.37) | TDP1HSD17B10 | |
| SCHEMBL233057 | 0.75 | ALDH1A1 (0.53) | TDP1ALDH1A1 | |
| SCHEMBL15295735 | 0.74 | — | — | |
| SCHEMBL13235783 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976512-B1 | NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-09-30 | — | — | EP | disclosed |
| US-8003800-B2 | Thiophene derivatives as S1P1/EDG1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-23 | — | — | US | disclosed |
| US-20100240717-A1 | NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-1976512-A1 | NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007080542-A1 | NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-07-19 | — | — | WO | disclosed |
| US-4362670-A | Allylation of carbon compounds | THE DOW CHEMICAL COMPANY (US) | 1982-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240717-A1 | NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | S1PR3, S1PR1, S1PR2 | TDP1 1373/4885ALDH1A1 1713/4885HSD17B10 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.